EA016592B1 - Трициклические производные изохинолина для лечения ожирения - Google Patents

Трициклические производные изохинолина для лечения ожирения Download PDF

Info

Publication number
EA016592B1
EA016592B1 EA200970849A EA200970849A EA016592B1 EA 016592 B1 EA016592 B1 EA 016592B1 EA 200970849 A EA200970849 A EA 200970849A EA 200970849 A EA200970849 A EA 200970849A EA 016592 B1 EA016592 B1 EA 016592B1
Authority
EA
Eurasian Patent Office
Prior art keywords
tetrahydro
azepino
indole
sulfonyl
phenylsulfonyl
Prior art date
Application number
EA200970849A
Other languages
English (en)
Russian (ru)
Other versions
EA200970849A1 (ru
Inventor
Йохан Ангбрант
Петер Брандт
Руне Рингом
Бенгт Линдквист
Original Assignee
Биовитрум Аб (Пабл)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биовитрум Аб (Пабл) filed Critical Биовитрум Аб (Пабл)
Publication of EA200970849A1 publication Critical patent/EA200970849A1/ru
Publication of EA016592B1 publication Critical patent/EA016592B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EA200970849A 2007-03-13 2008-03-13 Трициклические производные изохинолина для лечения ожирения EA016592B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0700611 2007-03-13
US202907P 2007-11-05 2007-11-05
PCT/EP2008/053002 WO2008110598A1 (en) 2007-03-13 2008-03-13 Tricyclic isoquinoline derivatives for treatment of obesity

Publications (2)

Publication Number Publication Date
EA200970849A1 EA200970849A1 (ru) 2010-04-30
EA016592B1 true EA016592B1 (ru) 2012-06-29

Family

ID=39462457

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970849A EA016592B1 (ru) 2007-03-13 2008-03-13 Трициклические производные изохинолина для лечения ожирения

Country Status (10)

Country Link
US (1) US8138333B2 (cg-RX-API-DMAC7.html)
EP (1) EP2134714A1 (cg-RX-API-DMAC7.html)
JP (1) JP2010520917A (cg-RX-API-DMAC7.html)
CN (1) CN101631787A (cg-RX-API-DMAC7.html)
AU (1) AU2008225753A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0808791A2 (cg-RX-API-DMAC7.html)
CA (1) CA2679346A1 (cg-RX-API-DMAC7.html)
EA (1) EA016592B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ579360A (cg-RX-API-DMAC7.html)
WO (1) WO2008110598A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101653707B1 (ko) * 2008-05-29 2016-09-02 알바니 몰레큘라 리써치, 인크. 5-ht3 수용체 조절제, 이의 제조 방법, 및 그의 용도
WO2011153359A1 (en) 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
WO2012106448A1 (en) * 2011-02-02 2012-08-09 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
EP2824106B1 (en) * 2012-03-06 2016-11-23 Takeda Pharmaceutical Company Limited Tricyclic compound
US10675283B2 (en) 2017-03-24 2020-06-09 University Of South Florida Compositions and methods for white to beige adipogenesis
CN109180687A (zh) * 2018-08-31 2019-01-11 山东轩德医药科技有限公司 一种瑞卡帕步中间体的制备方法
CN111961047A (zh) * 2020-08-19 2020-11-20 南通大学 一种6-乙氧基-3,4-二氢-2,7-萘啶-1(2h)-酮及其合成方法
CN115925658B (zh) * 2022-11-21 2024-02-27 常州佳德医药科技有限公司 一种2-氨基乙基呋喃的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833591A (en) * 1972-02-23 1974-09-03 Pfizer 1,3,4,5-tetrahydropyrrolo(4,3,2-d,e)isoquinolines and related compounds
US3950343A (en) * 1973-11-06 1976-04-13 Ayerst, Mckenna And Harrison Ltd. Pyrroloisoquinoline derivatives
US6133287A (en) * 1998-03-24 2000-10-17 Allelix Biopharmaceuticals Inc. Piperidine-indole compounds having 5-HT6 affinity
US20030229069A1 (en) * 2002-06-05 2003-12-11 Roche Palo Alto Llc 1-Sulfonyl-4-aminoalkoxy indole derivatives and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2194984C (en) 1994-07-26 2002-07-02 John Eugene Macor 4-indole derivatives as serotonin agonists and antagonists
GB9820113D0 (en) 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
AU767009B2 (en) 1998-12-11 2003-10-30 Virginia Commonwealth University Selective 5-HT6 receptor ligands
KR100823908B1 (ko) 2000-10-20 2008-04-21 바이오비트럼 에이비(피유비엘) 2-, 3-, 4-, 또는 5-치환-n1-(벤젠술포닐)인돌 및 이의치료 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833591A (en) * 1972-02-23 1974-09-03 Pfizer 1,3,4,5-tetrahydropyrrolo(4,3,2-d,e)isoquinolines and related compounds
US3950343A (en) * 1973-11-06 1976-04-13 Ayerst, Mckenna And Harrison Ltd. Pyrroloisoquinoline derivatives
US6133287A (en) * 1998-03-24 2000-10-17 Allelix Biopharmaceuticals Inc. Piperidine-indole compounds having 5-HT6 affinity
US20030229069A1 (en) * 2002-06-05 2003-12-11 Roche Palo Alto Llc 1-Sulfonyl-4-aminoalkoxy indole derivatives and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
L. STREKOWSKI ET AL.: "Synthesis of Analogs of the Ergot Alkaloids", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 37, 2000, pages 1495-1499, XP009101190, page 1496, compounds 17-19 *
R.E. BOWMAN ET AL.: "1,3,4,5-Tetrahydrobenz[cd]indoles and Related Compounds", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, no. 15, 1972, pages 1926-1932, XP009101189, page 1928, compound 35 *
Y. YOKOYAMA ET AL.: "Optically Active Total Synthesis of Claviciptic Acid.", JOURNAL OF ORGANIC CHEMISTRY, vol. 60, 1995, pages 1486-1487, XP002483151, page 1487, compound 14 *

Also Published As

Publication number Publication date
EA200970849A1 (ru) 2010-04-30
EP2134714A1 (en) 2009-12-23
BRPI0808791A2 (pt) 2017-05-02
NZ579360A (en) 2011-06-30
US20080293694A1 (en) 2008-11-27
JP2010520917A (ja) 2010-06-17
US8138333B2 (en) 2012-03-20
CA2679346A1 (en) 2008-09-18
AU2008225753A1 (en) 2008-09-18
WO2008110598A1 (en) 2008-09-18
CN101631787A (zh) 2010-01-20

Similar Documents

Publication Publication Date Title
EP1745040B9 (en) Azabicyclo(3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
CA3183656A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN104136437B (zh) N-(5s,6s,9r)-4-(2-氧代-2,3-二氢-1h-咪唑并[4,5-b]吡啶-1-基)哌啶-1-羧酸5-氨基-6-(2,3-二氟苯基)-6,7,8,9-四氢-5h-环庚三烯并[b]吡啶-9-基酯半硫酸盐
JP5150481B2 (ja) ドーパミンd3受容体のモジュレーターとしての3−(1,2,4−トリアゾール−3−イルアルキル)アザビシクロ(3.1.0)ヘキサン誘導体
JP5315244B2 (ja) アザビシクロヘキサン誘導体の使用
RU2434851C1 (ru) Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
US20060148818A1 (en) Novel tetraydrospiro(piperdine-2,7'- pyrrolo{3,2-b}pyridine derivatives and novel in-dole derivatives useful in the treatment of 5-ht6 receptor-related disorders
TW200813042A (en) Six membered heteroaromatic inhibitors targeting resistant kinase mutations
TW200836746A (en) Alpha2C adrenoreceptor agonists
JP5231992B2 (ja) ドーパミンd3受容体のモジュレーターとして有用なアザビシクロ(3.1.0)ヘキサン誘導体
CN110234638A (zh) 杂芳基苯氧基苯甲酰胺kappa阿片类配体
US8138333B2 (en) Sulfonyl-indole derivatives
US7803820B2 (en) 3-triazolylthiaalkyl-3-azabicyclo (3-1-O) hexanes and their use as dopamine D3 receptor ligands
JP5167123B2 (ja) ドーパミンd3受容体モジュレーターとしてのアザビシクロ[3.1.0]ヘキサン誘導体
JP2009507037A (ja) 5−HT2C受容体アゴニストとしての6−置換された2,3,4,5−テトラヒドロ−1H−ベンゾ[d]アゼピン
JP5179472B2 (ja) ドーパミンd3受容体についてのモジュレーターとして有用なスピロ化合物
HK1103016B (en) Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
KR20070020373A (ko) 5-HT6 수용체-관련 장애의 치료에 유용한 신규한 테트라히드로스피로{피페리딘-2,7'-피롤로[3,2-b]피리딘} 유도체 및 신규한 인돌 유도체

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU